EyePoint Pharmaceuticals: Navigating 4‑Fold Stock Swings Amid Negative Earnings & Growth Potential
EyePoint Pharmaceuticals’ Nasdaq stock shows a 4‑fold 52‑week swing, a negative P/E yet strong price‑to‑book ratio—investors eye its eye‑disease drug device pipeline for future profit potential.
2 minutes to read